Dispatch Biotherapeutics

Dispatch Biotherapeutics is a biotechnology company dedicated to engineering precision-targeted immunotherapies for the treatment of solid tumors. Utilizing its proprietary Dispatch platform, the company develops bispecific fusion proteins designed to deliver potent cytokines, such as Interleukin-12 and Interleukin-15, directly to the tumor microenvironment. This spatial targeting strategy aims to maximize local immune activation while avoiding the severe systemic toxicities that have historically limited cytokine therapies. Founded and incubated by MPM Capital, Dispatch Biotherapeutics is advancing a pipeline of programs intended to transform the landscape of cancer treatment through localized immune modulation.